Independent Advisor Alliance Novo Cure LTD Transaction History

Independent Advisor Alliance

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$56.44 - $118.81 $291,456 - $613,534	5,164 New	5,164 $310,000
Q3 2022 Nov 04, 2022	BUY	$67.99 - $89.57 $15,229 - $20,063	224 Added 5.21%	4,522 $344,000
Q2 2022 Aug 04, 2022	SELL	$56.6 - $89.9 $1,132 - $1,798	-20 Reduced 0.46%	4,298 $299,000
Q1 2022 May 06, 2022	SELL	$60.15 - $84.52 $9,323 - $13,100	-155 Reduced 3.47%	4,318 $358,000
Q4 2021 Feb 11, 2022	SELL	$75.08 - $121.99 $9,159 - $14,882	-122 Reduced 2.66%	4,473 $336,000
Q3 2021 Nov 01, 2021	SELL	$116.17 - $194.55 $62,150 - $104,084	-535 Reduced 10.43%	4,595 $534,000
Q2 2021 Aug 12, 2021	BUY	$130.4 - $225.58 $6,780 - $11,730	52 Added 1.02%	5,130 $1.14 Million
Q1 2021 May 14, 2021	SELL	$124.11 - $190.17 $5,957 - $9,128	-48 Reduced 0.94%	5,078 $671,000
Q4 2020 Feb 11, 2021	BUY	$112.16 - $174.14 $27,591 - $42,838	246 Added 5.04%	5,126 $887,000
Q3 2020 Nov 04, 2020	SELL	$58.05 - $111.31 $56,772 - $108,861	-978 Reduced 16.7%	4,880 $543,000
Q2 2020 Aug 06, 2020	BUY	$57.2 - $74.41 $335,077 - $435,893	5,858 New	5,858 $347,000

263

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $2.07B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Independent Advisor Alliance, based on Form 13F filings with the SEC.

Stay updated on Independent Advisor Alliance with notifications on news.